Day One Agenda

7:00 am - 4:00 pm | Boston, MA

Want to see the agenda, speaker faculty and more all in one place? Download the full Event Guide.

7:00 am Registration

7:55 am Chair’s Opening Remarks

Examining Meaningful Methods to Target Neoantigens for Accelerated Field Developments

8:00 am A Landscape Analysis of Neoantigens Used in Cancer Vaccines

Synopsis

  • Providing an overview of the current preclinical and clinical view of cancer vaccines which utilize a neoantigen
  • Uncovering the current neoantigen selection technologies and current trends
  • Highlighting the future directions of the neoantigen space

8:30 am Advancing the New Era of Neoantigen Discovery Using HERVs

Synopsis

  • Looking at non-classical neoantigens, their sequencing and data analysis issues being used to identify retrovirus antigens
  • Communicating the latest advancements of the non-coding region being used in neoantigen discovery
  • Learning if they are shared based on disease state or on populations and uncovering if all retroviruses are disease-based

9:00 am Session Reserved for Polypeptide

9:30 am Speed Networking

Synopsis

This session is the ideal opportunity to take advantage of informal networking time and understand who is also prioritizing and overcoming challenges within the various sectors of the neoantigen and cancer vaccines world

10:00 am Morning Break & Networking

Testing the Validity of Bioinformatics & AI to Select the Right Neoantigens

10:30 am Using AI-powered bioinformatics and antigen presenting cells to create a measurable and trackable precision TIL product targeting clonal neoantigens

Synopsis

  • Finding clonal neoantigens and highlighting their importance compared to other subsets of neoantigens
  • Exploring a specific technology to target clonal neoantigens
  • Highlighting the highly complicated process and data management required to develop the platform based on arguably the biggest real-world data set

11:00 am Session Reserved for NEC OncoImmunity

11:30 am Panel Discussion – Engineering Matters to Counter the Tumor Microenvironment (TME) for Better Persistence

  • Joel Sandler Principal Cancer Cell Therapy Lead, Lumanity
  • Ramon Tiu Head Of Oncology Cell Therapy Development, Takeda

Synopsis

  • Modifications to achieve blockade of checkpoints (e.g., PD1 KO) or other ligand signalling (e.g., TGFbeta dominant negative)
  • ‘Armouring’ cells with membrane-bound or secreted cytokines
  • Modulation of TME itself to increase tumor ‘warmth’
  • Dual- and multi-targeting to prevent antigen escape
  • Increasing the safety of therapies by adding ‘switches’ to turn on/off expression of required matters

12:00 pm Lunch & Networking

Assessing Immune Biomarkers in Tumor Microenvironments to Provide Predictive Responses

1:00 pm Observing Biomarkers for Vaccine Checkpoints & Combinations

Synopsis

  • Establishing biomarkers for the epithelial checkpoint to predict response
  • Identifying novel biomarkers in checkpoint inhibitors and comparing them to biomarkers within combination approaches

1:30 pm Use of ctDNA for Real-Time Monitoring of Clinical Benefit in Cancer Patient

Synopsis

  • Looking at ctDNA as a biomarker for evaluating patient responses
  • Navigating different avenues to reach the same results
  • Discussing the views on what actually matters

2:00 pm Afternoon Break & Networking

Utilizing Learnings from Novel Clinical Data Around Neoantigen Targeted Therapies

2:30 pm GT-EPIC™ Platform Based Personalized Cancer Vaccines to Treat Patients with Advanced Hepatocellular Carcinoma in Combination with PD1 Checkpoint Immunotherapy

  • Niranjan Sardesai Co-Founder, President & Chief Executive Officer, Geneos Therapeutics

Synopsis

  • Sharing clinical data highlighting objective responses evaluated via RECIST 1.1
  • Understanding what can biomarkers inform us for predicting cancer vaccine driven clinical and immunological responses in checkpoint combinations

3:00 pm Neoantigen Targeted Therapies in Combination with Immune Checkpoint Inhibitors: Learnings from Novel Clinical Data

  • Karin Jooss Head of Research & Development, Gritstone bio

Synopsis

  • Heterologous prime/boost vaccination utilizing a Chimpanzee Adenoviral vector prime, and a self-amplifying RNA (samRNA) boost drives robust neoantigen specific T-cell responses
  • Less is more: Lower doses of samRNA boost superior T-cell responses than high dose samRNA
  • Neoantigen specific T-cell responses provide therapeutic benefit to patients with  advanced stage MSS-CRC

3:30 pm Important Aspects of Neo-Epitope Identification & Their Relevance in Clinical Trials

Synopsis

  • Discussing the important features for neo-epitope identification
  • Understanding how AI has improved identification of neo-epitopes and further improvement needed
  • Uncovering how to use AI predictions in understanding clinical dat

4:00 pm End of conference day 1

4:10 pm Drinks reception hosted by Polypeptide & Scientific Poster Session

Synopsis

After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda allowing you to connect with your peers in a relaxed atmosphere and continue to develop new and existing relationships. During this session, scientific posters will be presented on the cutting-edge advances of neoantigen therapeutics.